IC
Incyte Corporation (Wilmington, DE). 2024 revenue ~$4.1B. JAKAFI (ruxolitinib) for myelofibrosis. Opzelura (ruxolitinib cream). Monclara (itacitinib). JAK1/2 inhibitor pioneer. CAR-T pipeline with MorphoSys.
IC
Incyte Corporation
@incyte
Joined July 2026
6 Following6 Followers